相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases
Fawn Qian et al.
CANCER RESEARCH (2009)
Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer
Soundararajan Krishnaswamy et al.
CLINICAL CANCER RESEARCH (2009)
Angioinhibitory Action of NK4 Involves Impaired Extracellular Assembly of Fibronectin Mediated by Perlecan-NK4 Association
Katsuya Sakai et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
MET, HGF, EGFR, and PXN Gene Copy Number in Lung Cancer Using DNA Extracts from FFPE Archival Samples and Prognostic Significance
Rajani Kanteti et al.
JOURNAL OF ENVIRONMENTAL PATHOLOGY TOXICOLOGY AND ONCOLOGY (2009)
MET Pathway as a Therapeutic Target
Eric S. Kim et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo
Sean G. Buchanan et al.
MOLECULAR CANCER THERAPEUTICS (2009)
No Somatic Genetic Change in the Paxillin Gene in Nonsmall-Cell Lung Cancer
Karine Pallier et al.
MOLECULAR CARCINOGENESIS (2009)
Novel treatment of medullary thyroid cancer
Masahiro Sugawara et al.
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY (2009)
C-elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C-elegans vulva phenotypes
Shahid S. Siddiqui et al.
CANCER BIOLOGY & THERAPY (2008)
Paxillin is a target for somatic mutations in lung cancer: Implications for cell growth and invasion
Ramasamy Jagadeeswaran et al.
CANCER RESEARCH (2008)
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors
Ultan McDermott et al.
CANCER RESEARCH (2008)
Expression and Mutational Analysis of MET in Human Solid Cancers
Patrick C. Ma et al.
GENES CHROMOSOMES & CANCER (2008)
被撤回的出版物: Down-regulation of Micro-RNA-1 (miR-1) in Lung Cancer SUPPRESSION OF TUMORIGENIC PROPERTY OF LUNG CANCER CELLS AND THEIR SENSITIZATION TO DOXORUBICIN-INDUCED APOPTOSIS BY miR-1 (Retracted article. See vol. 293, pg. 12945, 2018)
Mohd W. Nasser et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
James Bean et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts
H. Toni Jun et al.
CLINICAL CANCER RESEARCH (2007)
Pharmacokinetics and safety of a fully human hepatocyte growth factor antibody, AMG 102, in cynomolgus monkeys
Tarundeep Kakkar et al.
PHARMACEUTICAL RESEARCH (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms
Helen Y. Zou et al.
CANCER RESEARCH (2007)
A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts
Neelu Puri et al.
CANCER RESEARCH (2007)
A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer
Grzegorz S. Nowakowski et al.
CLINICAL CANCER RESEARCH (2006)
Inhibition of c-Met and prevention of spontaneous metastatic spreading by the 2-indolinone RPI-1
Giuliana Cassinelli et al.
MOLECULAR CANCER THERAPEUTICS (2006)
A selective small molecule c-MET inhibitor, PHA665752, cooperates with rapamycin
PC Ma et al.
CLINICAL CANCER RESEARCH (2005)
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer
MP Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Targeting the tumor and its microenvironment by a dual-function decoy Met receptor
P Michieli et al.
CANCER CELL (2004)
Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer
G Maulik et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2002)
K252a inhibits the oncogenic properties of Met, the HGF receptor
A Morotti et al.
ONCOGENE (2002)
Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition
G Maulik et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2002)
Modulation of metastasis phenotypes of non-small cell lung cancer cells by 17-allylamino 17-demethoxy geldanamycin
DM Nguyen et al.
ANNALS OF THORACIC SURGERY (2000)
Disassociation of met-mediated biological responses in vivo: the natural hepatocyte growth factor/scatter factor splice variant NK2 antagonizes growth but facilitates metastasis
T Otsuka et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
分享论文
